PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma
NCT06125223
·
clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
45
Enrollment
OTHER
Sponsor class
Conditions
Squamous Cell Carcinoma of Head and Neck
Neoadjuvant Therapy
Immunotherapy
Sponsor
Xijing Hospital